Back to Search
Start Over
Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer
- Source :
- BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020), BMC Cancer
- Publication Year :
- 2020
- Publisher :
- Research Square Platform LLC, 2020.
-
Abstract
- Background The prognostic nutritional index (PNI), which is an easily calculated nutritional index, is significantly associated with patient outcomes in various solid malignancies. This study aimed to evaluate the prognostic impact of PNI changes in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC). Methods We reviewed patients with breast cancer who underwent NAC and a subsequent surgery for breast cancer between 2005 and 2016. PNI before and after NAC were calculated using the following formula: 10 × serum albumin (g/dl) + 0.005 × total lymphocyte count/mm3. The relationship between PNI and prognosis was retrospectively analyzed. Results In total, 191 patients were evaluated. There was no significant difference in disease-free survival (DFS) between the pre-NAC PNI high group and the pre-NAC PNI low group (cutoff: 53.1). However, PNI decreased in 181 patients (94.7%) after NAC and the mean PNI also significantly decreased after NAC from 52.6 ± 3.8 pre-NAC to 46.5 ± 4.4 post-NAC (p p = 0.015). Moreover, high ΔPNI was an independent risk factor of DFS on multivariate analysis (p = 0.042). Conclusions High decrease of PNI during NAC predicts poor prognosis. Thus, maintaining the nutritional status during NAC may result in better treatment outcomes in patients with breast cancer.
- Subjects :
- 0301 basic medicine
Oncology
Adult
Cancer Research
medicine.medical_specialty
Poor prognosis
Multivariate analysis
Disease-free survival
medicine.medical_treatment
Nutritional Status
Breast Neoplasms
Serum Albumin, Human
Neoadjuvant chemotherapy
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Breast cancer
Chemotherapy induced
Surgical oncology
Internal medicine
Genetics
medicine
Humans
In patient
Anthracyclines
Lymphocyte Count
Risk factor
Retrospective Studies
Chemotherapy
business.industry
Prognostic nutritional index
Middle Aged
medicine.disease
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Analysis
Neoadjuvant Therapy
030104 developmental biology
Nutrition Assessment
Treatment Outcome
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Female
business
Research Article
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020), BMC Cancer
- Accession number :
- edsair.doi.dedup.....c2c575642e3c0c3779a71d3f11b31807
- Full Text :
- https://doi.org/10.21203/rs.2.12820/v4